Global Vasculitis Market Research and Forecast 2018-2023

  • ID: 4537394
  • Report
  • Region: Global
  • Orion Market Research Private Limited
1 of 4

FEATURED COMPANIES

  • Abbvie Inc.
  • Astrazeneca Plc
  • Celgene Corporation
  • Chugai Pharma Usa, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • MORE
The market for vasculitis across the globe is expected to propel significantly during the forecast period. The factors driving the vasculitis market are rising incidences of metabolic disorders and circulatory diseases such as peripheral arterial disease (PAD) and high demand for minimally invasive procedures. In addition, the rising healthcare expenditure and R&D vasculitis treatment and supportive reimbursement policies are estimated to impact the market positively during the forecast period.

Due to the advancement in the treatment, vasculitis can be controlled and now it can be completely cured. However, the side effect associated to treatment such as weight gain, diabetes and bone thinning are now serious issue. Many researches are going on to identify the main cause of vasculitis and various research institutes are providing funds for these researches. For instance, University of Cambridge have received funding from Arthritis Research UK to investigate cause of disease called ANCA-associated vasculitis.

Geographically, North America was a leader and held the highest market share in 2017 which is expected to sustain during the forecast period as well. This is mainly due to the growing prevalence of vasculitis which is increasing the demand for the treatment of vasculitis in the region. They ke driving forces expected to boost the market of vasculitis in North America are rising healthcare expenditure and R&D in vasculitis treatment and supportive reimbursement policies. Furthermore, Europe region is also considered to be one of major region mainly due to rising incidence of higher incidence of granulomatosis with polyangiitis (GPA) and high demand for minimally invasive procedures. APAC is expected to be the fastest growing region due to increasing higher incidence of microscopic polyangiitis (MPA) in China and Japan. The report includes detailed market overview, market determinants, company profiling, market segmentation, geographical analysis, strategic recommendations, key company analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.

Key players of vasculitis market include GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Genentech, Inc. Celgene Corporation, Ablynx, Gilead, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, Eli Lilly and Company, and Merck & Co., Inc. These market players are increasingly competing against each other by adopting different market strategies such as merger & acquisition, partnership & collaboration and so on. The development of drugs for the treatment of vasculitis will strengthen the competitive environment of the market.

Research Methods and Tools:

The market study of vasculitis market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalogue.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbvie Inc.
  • Astrazeneca Plc
  • Celgene Corporation
  • Chugai Pharma Usa, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • MORE
Chapter 1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

Chapter 2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulations
2.3.1.1. United States
2.3.1.2. European Union
2.3.1.3. China
2.3.1.4. India

Chapter 3. Market Determinant
3.1. Motivators
3.1.1. Rising Incidences of Metabolic Disorders and Circulatory Diseases Such as Peripheral Arterial Disease (Pad)
3.1.2. Rising Healthcare Expenditure and R&D Vasculitis Treatment
3.1.3. High Demand For Minimally Invasive Procedures
3.1.4. Supportive Reimbursement Policies
3.2. Restraints
3.2.1. High Cost of Vasculitis Diagnosis and Treatment
3.2.2. Lack of Awareness Among People
3.3. Opportunities
3.3.1. Technological Advancements & Innovations Such as Sequential Magnetic Resonance Imaging Magnetic Resonance Angiography (Mrimra)
3.3.2. Large Number of Pipeline Products

Chapter 4. Market Segmentation
4.1. Global Vasculitis Market, By Type
4.1.1. Large Vessels
4.1.1.1. Behçet’S Disease
4.1.1.2. Cogan’S Syndrome
4.1.1.3. Giant Cell Arteritis (Temporal Arteritis)
4.1.1.4. Polymyalgia Rheumatica
4.1.1.5. Takayasu’S Arteritis (Aortic Arch Syndrome)
4.1.2. Medium Vessels
4.1.2.1. Buerger’S Disease (Thromboangiitis)
4.1.2.2. Central Nervous System Vasculitis
4.1.2.3. Kawasaki’S Disease (Mucocutaneous Lymph Node Disease)
4.1.2.4. Polyarteritis Nodosa
4.1.3. Small Vessels
4.1.3.1. Churg-Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis)
4.1.3.2. Cryoglobulinemia Vasculitis
4.1.3.3. Immunoglobulin a Vasculitis
4.1.3.4. Hypersensitivity Vasculitis (Allergic Vasculitis, Cutaneous Vasculitis, Leukocytoclastic Vasculitis)
4.1.3.5. Microscopic Polyangiitis
4.2. Global Vasculitis Market, By Diagnosis Tests
4.2.1. Blood Test
4.2.2. Urine Test
4.2.3. Imaging Test
4.2.4. Angiography
4.2.5. Biopsy
4.2.6. Other (Erythrocyte Sedimentation Rate (Esr), C–Reactive Protein (Crp), Ct Scan, Anca Tests)
4.3. Global Vasculitis Market, By Therapeutic Class
4.3.1. Corticosteroids (Such as Prednisone, Prednisolone, and Methylprednisolone)
4.3.2. Immunosuppressants
4.3.3. Biologics
4.4. Global Vasculitis Market By End Users
4.4.1. Hospitals and Clinics
4.4.2. Diagnosis Center
4.4.3. Research Institutes
4.4.4. Others

Chapter 5. Competitive Landscape
5.1. Key Company Analysis
5.2. Key Strategy Analysis

Chapter 6. Regional Analysis
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. U.K
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. ROE
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. ROAPAC
6.4. Rest of the World

Chapter 7. Company Profiles
7.1. Abbvie Inc.
7.2. Ablynx Nv
7.3. Amgen Inc.
7.4. Anthera Pharmaceuticals‚ Inc.
7.5. Aspen Pharmacare Holdings Limited
7.6. Astrazeneca Plc
7.7. Baxter
7.8. Biogen
7.9. Bristol-Myers Squibb Company
7.10. Celgene Corporation
7.11. Celltrion Inc.
7.12. Chemocentryx, Inc.
7.13. Chugai Pharma Usa, Inc.
7.14. Eisai Co., Ltd.
7.15. Eli Lilly and Company
7.16. F. Hoffmann-La Roche Ltd.
7.17. Genentech, Inc.
7.18. Gilead
7.19. Glaxosmithkline Plc
7.20. Human Genome Sciences, Inc.
7.21. Johnson & Johnson Services, Inc.
7.22. Merck & Co., Inc.
7.23. Mitsubishi Tanabe
7.24. Novartis Ag
7.25. Novo Nordisk A/S
7.26. Ono Pharmaceutical Co., Ltd.
7.27. Pfizer Inc.
7.28. Sanofi S.A.
7.29. Ucb S.A.
7.30. Vifor Fresenius Medical Care Renal Pharma (Vfmcrp)

List of Tables:
Table 1 Global Vasculitis Market Research and Analysis By Type, 2017-2023 ($ Million)
Table 2 Global Large Vessels Market Research and Analysis, 2017-2023 ($ Million)
Table 3 Global Medium Vessels Market Research and Analysis, 2017-2023 ($ Million)
Table 4 Global Small Vessels Market Research and Analysis, 2017-2023 ($ Million)
Table 5 Global Vasculitis Market Research and Analysis By Diagnosis Tests, 2017-2023 ($ Million)
Table 6 Global Blood Test Market Research and Analysis, 2017-2023 ($ Million)
Table 7 Global Urine Test Market Research and Analysis, 2017-2023 ($ Million)
Table 8 Global Imaging Test Market Research and Analysis, 2017-2023 ($ Million)
Table 9 Global Biopsy Test Market Research and Analysis, 2017-2023 ($ Million)
Table 10 Global Other Test Market Research and Analysis, 2017-2023 ($ Million)
Table 11 Global Vasculitis Market Research and Analysis By Therapeutic Class, 2017-2023 ($ Million)
Table 12 Global Corticosteroids Market Research and Analysis, 2017-2023 ($ Million)
Table 13 Global Immunosuppressants Market Research and Analysis, 2017-2023 ($ Million)
Table 14 Global Biologics Market Research and Analysis, 2017-2023 ($ Million)
Table 15 Global Vasculitis Market Research and Analysis By End User, 2017-2023 ($ Million)
Table 16 Global Hospitals and Clinics Market Research and Analysis, 2017-2023 ($ Million)
Table 17 Global Research Institues Market Research and Analysis, 2017-2023 ($ Million)
Table 18 Global Diagnosis Center Market Research and Analysis, 2017-2023 ($ Million)
Table 19 Global Other End User Market Research and Analysis, 2017-2023 ($ Million)
Table 20 Global Vasculitis Market Research and Analysis By Geography, 2017-2023 ($ Million)
Table 21 North American Vasculitis Market Research and Analysis By Country, 2017-2023 ($ Million)
Table 22 North American Vasculitis Market Research and Analysis By Type, 2017-2023 ($ Million)
Table 23 North American Vasculitis Market Research and Analysis By Diagnosis Test, 2017-2023 ($ Million)
Table 24 North American Vasculitis Market Research and Analysis By Therapeutic Class, 2017-2023 ($ Million)
Table 25 North American Vasculitis Market Research and Analysis By End User, 2017-2023 ($ Million)
Table 26 European Vasculitis Market Research and Analysis By Country, 2017-2023 ($ Million)
Table 27 European Vasculitis Market Research and Analysis By Type, 2017-2023 ($ Million)
Table 28 European Vasculitis Market Research and Analysis By Diagnosis Tests, 2017-2023 ($ Million)
Table 29 European Vasculitis Market Research and Analysis By Therapeutic Class, 2017-2023 ($ Million)
Table 30 European Vasculitis Market Research and Analysis By End User, 2017-2023 ($ Million)
Table 31 APAC Vasculitis Market Research and Analysis By Country, 2017-2023 ($ Million)
Table 32 APAC Vasculitis Market Research and Analysis By Type, 2017-2023 ($ Million)
Table 33 APAC Vasculitis Market Research and Analysis By Diagnosis Tests, 2017-2023 ($ Million)
Table 34 APAC Vasculitis Market Research and Analysis By Therapeutic Class, 2017-2023 ($ Million)
Table 35 APAC Vasculitis Market Research and Analysis By End User, 2017-2023 ($ Million)
Table 36 RoW Vasculitis Market Research and Analysis By Type, 2017-2023 ($ Million)
Table 37 RoW Vasculitis Market Research and Analysis By Diagnosis Tests, 2017-2023 ($ Million)
Table 38 RoW Vasculitis Market Research and Analysis By Therapeutic Class, 2017-2023 ($ Million)
Table 39 RoW Vasculitis Market Research and Analysis By End User, 2017-2023 ($ Million)

List of Figures:
Figure 1 Global Vasculitis Market Share By Type, 2017 Vs 2023 (%)
Figure 2 Global Vasculitis Market Share By Diagnosis Tests, 2017 Vs 2023 (%)
Figure 3 Global Vasculitis Market Share By Therapeutic Class, 2017 Vs 2023 (%)
Figure 4 Global Vasculitis Market Share By End User, 2017 Vs 2023 (%)
Figure 5 Us Vasculitis Market Size, 2017-2023 ($ Million)
Figure 6 Canada Vasculitis Market Size, 2017-2023 ($ Million)
Figure 7 UK Vasculitis Market Size, 2017-2023 ($ Million)
Figure 8 France Vasculitis Market Size, 2017-2023 ($ Million)
Figure 9 Germany Vasculitis Market Size, 2017-2023 ($ Million)
Figure 10 Italy Vasculitis Market Size, 2017-2023 ($ Million)
Figure 11 Spain Vasculitis Market Size, 2017-2023 ($ Million)
Figure 12 ROE Vasculitis Market Size, 2017-2023 ($ Million)
Figure 13 India Vasculitis Market Size, 2017-2023 ($ Million)
Figure 14 China Vasculitis Market Size, 2017-2023 ($ Million)
Figure 15 Japan Vasculitis Market Size, 2017-2023 ($ Million)
Figure 16 ROAPAC Vasculitis Market Size, 2017-2023 ($ Million)
Figure 17 Rest of the World Vasculitis Market Size, 2017-2023 ($ Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbvie Inc.
  • Ablynx Nv
  • Amgen Inc.
  • Anthera Pharmaceuticals‚ Inc.
  • Aspen Pharmacare Holdings Limited
  • Astrazeneca Plc
  • Baxter
  • Biogen
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion Inc.
  • Chemocentryx, Inc.
  • Chugai Pharma Usa, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead
  • Glaxosmithkline Plc
  • Human Genome Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe
  • Novartis Ag
  • Novo Nordisk A/S
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Ucb S.A.
  • Vifor Fresenius Medical Care Renal Pharma (Vfmcrp)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll